Metabolic Health Articles - Page 39

Why US Patients Sue Ozempic Makers Over Gastroparesis, Vision Loss

Lawsuits against Ozempic manufacturer Novo Nordisk are exploding in the US, with patients alleging the company hid severe side effects like gastroparesis and sudden vision loss from semaglutide. Originally a type 2 diabetes drug, Ozempic's popularity as a weight loss shot has sparked debates on safety and marketing. Despite high demand, experts urge medical supervision to avoid serious risks.

Shotlee·Mar 25, 2026·5 min read

GLP-1 Medications

GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom

High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.

Shotlee·Mar 25, 2026·6 min read

GLP-1 Medications

Novo Nordisk Bets on Clinical Depth vs Discounts for Semaglutide Generics in ...

After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.

Shotlee·Mar 25, 2026·5 min read

Regulatory News

India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge

India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.

Shotlee·Mar 25, 2026·5 min read

GLP-1 Medications

GLP-1 Therapies: Risks and Rewards Across Conditions

GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.

Shotlee·Mar 24, 2026·5 min read

Weight Management

Experts Stress Holistic Approach to Semaglutide for Weight Management

At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.

Shotlee·Mar 24, 2026·6 min read

Weight Loss & Metabolic Health

What to Do When Tirzepatide Stops Working: Shift to Retatrutide

If Tirzepatide worked initially but now you've hit a plateau, it's not failure—it's metabolic adaptation signaling the next phase. California Trim Clinic is leading the shift to retatrutide, a triple-pathway therapy targeting energy expenditure for sustained results. Patients are moving beyond plateaus with physician-guided care.

Shotlee·Mar 24, 2026·4 min read

GLP-1 Medications

Telangana Warns on Semaglutide Misuse for Weight Loss

Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.

Shotlee·Mar 24, 2026·5 min read

Regulatory Updates

India Steps Up Oversight on GLP-1 Drugs Over Improper Practices

India's drug regulator is cracking down on GLP-1 weight loss drugs due to improper sales and promotions. Inspections across 49 entities revealed violations, leading to notices and potential license cancellations. With semaglutide generics now available post-patent expiry, authorities emphasize prescription-only use by specialists.

Shotlee·Mar 24, 2026·4 min read

Metabolic Health

Latest Articles

Why US Patients Sue Ozempic Makers Over Gastroparesis, Vision Loss

GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom

Novo Nordisk Bets on Clinical Depth vs Discounts for Semaglutide Generics in ...

India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge

GLP-1 Therapies: Risks and Rewards Across Conditions

Experts Stress Holistic Approach to Semaglutide for Weight Management

What to Do When Tirzepatide Stops Working: Shift to Retatrutide

Telangana Warns on Semaglutide Misuse for Weight Loss

India Steps Up Oversight on GLP-1 Drugs Over Improper Practices

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less

Ozempic, Mounjaro & More: Yale Study Exposes Risky Online GLP-1 Prescribing

GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia

Beyond Healthspan: The New Midlife Goal for Men

Ozempic and Similar Weight-Loss Medications Linked to 30% Lower Breast Cancer Risk